K. Peerlinck

B. Meyns, W. Droogné, F. Rega, 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Recessive inheritance of von Willebrand's disease type I

P. Reitsma, J. Eikenboom, K. Peerlinck, 1993, The Lancet.

Eliminating viral hepatitis C in Belgium: the micro-elimination approach

J. Lazarus, M. Jadoul, F. Nevens, 2020, BMC Infectious Diseases.

Factor VIII inhibitors

F. Rosendaal, D. Bevan, J. Vermylen, 1993, The Lancet.

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells

R. d'Oiron, K. Peerlinck, J. Saint-Remy, 2011, Journal of thrombosis and haemostasis : JTH.

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.

J. Vermylen, M. Hoylaerts, J. Arnout, 1999, Blood.

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

J. Vermylen, B. Maillère, K. Peerlinck, 2003, Blood.

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.

M. Levi, K. Peerlinck, E. Mauser-Bunschoten, 1998, The Netherlands journal of medicine.

Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey

S. Simoens, I. Huys, C. Hermans, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Fatal complication of desmopressin

J. Vermylen, K. Peerlinck, S. Hartmann, 1995, The Lancet.

Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene

T. de Ravel, P. Verhamme, K. Peerlinck, 2014, Acta clinica Belgica.

Hepatitis C virus‐RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: Evidence for viral replication in peripheral blood mononuclear cells

S. Yap, J. Vermylen, K. Peerlinck, 1994, Journal of medical virology.

Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters

P. Verhamme, P. Kamphuisen, M. Kruip, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography

M. Hoylaerts, J. Arnout, K. Peerlinck, 2008, Thrombosis and Haemostasis.

Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.

P. Verhamme, S. Middeldorp, K. Peerlinck, 2015, Thrombosis research.

Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation

P. Verhamme, K. Peerlinck, T. Vanassche, 2014, Journal of Thrombosis and Thrombolysis.

The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer

Marloes R. Tijssen, Chantal Thys, Kathleen Freson, 2017, Haematologica.

MK‐383 (L‐700,462), a Selective Nonpeptide Platelet Glycoprotein 1Ib/IIIa Antagonist, Is Active in Man

J. Vermylen, J. Barrett, M. Goldberg, 1993, Circulation.

Factor VIII deficiency does not protect against atherosclerosis

H. Büller, E. Groot, P. Verhamme, 2012, Journal of thrombosis and haemostasis : JTH.

A coagulation defect arising from heterozygous premature termination of tissue factor.

Chad A. Cowan, W. Ouwehand, R. Westrick, 2020, The Journal of clinical investigation.

more than the quantification of lupus anticoagulants Thrombotic risk assessment in the antiphospholipid syndrome requires

M. Hoylaerts, K. Peerlinck, K. Devreese, 2013 .

Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants.

M. Hoylaerts, K. Peerlinck, K. Devreese, 2010, Blood.

Anticoagulant therapy in COVID-19 critically ill: Should we go for more? // Antithrombotische Therapie sehr kranker COVID-19-Patienten

K. Huber, P. Verhamme, A. Wilmer, 2020 .

Pharmacotherapy with oral Xa inhibitors for venous thromboembolism

P. Verhamme, K. Peerlinck, T. Vanassche, 2015, Expert opinion on pharmacotherapy.

Molecular basis for type 1 antithrombin deficiency: identification of two novel point mutations and evidence for a de novo splice site mutation.

W. Lissens, I. Liebaers, K. Peerlinck, 1994, Blood.

Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study

S. Simoens, I. Huys, C. Hermans, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Whole genome sequencing of a sporadic primary immunodeficiency cohort

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2018, Nature.

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing

P. Verhamme, S. Janssens, B. Vandenberk, 2022, Research and Practice in Thrombosis and Haemostasis.

Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization

P. Verhamme, S. Janssens, K. Peerlinck, 2021, Seminars in Thrombosis and Hemostasis.

Experiences with continuous infusion of recombinant activated factor VII.

M. Morfini, J. Goudemand, C. Négrier, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Drugs affecting blood coagulation, fibrinolysis and hemostasis

J. Vermylen, K. Peerlinck, 2001 .

Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients

M. Hoylaerts, K. Peerlinck, K. Devreese, 2011, Thrombosis and Haemostasis.

Antidote strategies to reverse anticoagulation with TB‐402, a long‐acting partial inhibitor of factor VIII

P. Verhamme, M. Hoylaerts, K. Peerlinck, 2012, Journal of thrombosis and haemostasis : JTH.

Monoclonal gammopathy of undetermined significance: significant beyond hematology.

P. Verhamme, M. Delforge, K. Peerlinck, 2009, Mayo Clinic proceedings.

FVIII production by human lung microvascular endothelial cells.

C. Kirkpatrick, M. Hermanns, F. Rega, 2006, Blood.

Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders

Sylvia Richardson, Augusto Rendon, Sjoert B. G. Jansen, 2015, Genome Medicine.

Inherited missense variants that affect GFI1B function do not necessarily cause bleeding diatheses

W. Ouwehand, K. Downes, R. Favier, 2019, Haematologica.

A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies

Sylvia Richardson, Kathleen Stirrups, Wendy N. Erber, 2016, Science Translational Medicine.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor

J. Vermylen, K. Peerlinck, 1999, Thrombosis and Haemostasis.

The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders

P. Verhamme, K. Peerlinck, M. Jacquemin, 2015, Journal of thrombosis and haemostasis : JTH.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

M. Ozelo, D. Quon, A. Leavitt, 2022, The New England journal of medicine.

Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter.

P. Reitsma, R. Bertina, K. Peerlinck, 1993, Blood.

Characteristics of inhibitors in mild/moderate haemophilia A

K. Peerlinck, M. Jacquemin, Marc Jacquemin, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.

Ania, Eleanor, Dewhurst, 2018 .

Optimal care of inhibitor patients during surgery

J. Vermylen, J. Vermylen, K. Peerlinck, 1998, European journal of haematology. Supplementum.

Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition

K. Goffin, P. Verhamme, M. Hoylaerts, 2018, Thrombosis and Haemostasis.

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders

F. Rosendaal, P. Giangrande, N. Özdemir, 2012, Journal of thrombosis and haemostasis : JTH.

Acute hepatitis A in patients with haemophilia A

J. Vermylen, K. Peerlinck, 1993, The Lancet.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH

J. Oldenburg, M. Makris, G. Castaman, 2018, Journal of thrombosis and haemostasis : JTH.

Mild haemophilia: a disease with many faces and many unexpected pitfalls

K. Peerlinck, M. Jacquemin, M. Jacquemin, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial

F. Comte, M. Prins, L. Morssink, 2022, The Lancet.

Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura

H. Deckmyn, F. Peyvandi, R. Palla, 2010, Journal of thrombosis and haemostasis : JTH.

The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays

P. Verhamme, K. Peerlinck, M. Jacquemin, 2018, International journal of laboratory hematology.

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

F. Nevens, K. Peerlinck, G. Robaeys, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

5 Inhibitory and activating human antiplatelet antibodies

H. Deckmyn, K. Peerlinck, K. Vanhoorelbeke, 1998 .

Hepatitis C virus genotypes in belgian hemophiliacs

S. Yap, J. Vermylen, K. Peerlinck, 1995, Journal of medical virology.

The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG‐Arg301 to be distinguished from hypofibrinogenemia

K. Peerlinck, M. Jacquemin, K. Freson, 2017, International journal of laboratory hematology.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

P. Moreau, T. Lambert, C. Rothschild, 2006, Seminars in hematology.

Inhibitors to Factor VIII—Mild and Moderate Hemophilia

K. Peerlinck, M. Jacquemin, 2007 .

Molecular mechanisms of mild and moderate hemophilia A

M. de Maeyer, K. Peerlinck, J. Saint-Remy, 2003, Journal of thrombosis and haemostasis : JTH.

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

J. Vermylen, L. Vander Elst, K. Thielemans, 2000, Blood.

Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes

J. Vermylen, M. Hoylaerts, J. Vermylen, 1999, Thrombosis and Haemostasis.

Point mutations scattered in the FVIII C1 and C2 domains reduce FVIII binding to vWF and are associated to mild/moderate hemophilia A

R. Schwaab, J. Vermylen, K. Peerlinck, 1999 .

The factor VIII treatment history of non‐severe hemophilia A

C. Santoro, K. Fischer, M. Kruip, 2020, Journal of Thrombosis and Haemostasis.

Optimization of the detection of inhibitory autoantibodies against the VWF‐cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay

K. Peerlinck, M. Jacquemin, D. Dierickx, 2020, International journal of laboratory hematology.

Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial.

P. Moons, S. Fieuws, W. Peetermans, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure.

J. Vermylen, L. Vanhees, R. De vos, 2005, Blood.

Clinical gait features are associated with MRI findings in patients with haemophilic ankle arthropathy

F. Staes, C. Hermans, K. Peerlinck, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Reliability and clinical features associated with the IPSG MRI tibiotalar and subtalar joint scores in children, adolescents and young adults with haemophilia

C. Hermans, K. Peerlinck, S. Lobet, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Acquired multi‐segment foot kinematics in haemophilic children, adolescents and young adults with or without haemophilic ankle arthropathy

F. Staes, C. Hermans, K. Peerlinck, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

C. Hermans, V. Jiménez‐Yuste, S. Chebon, 2019, The Lancet. Haematology.

Paediatric patients with blood‐induced ankle joint arthritis demonstrate physiological foot joint mechanics and energetics during walking

F. Staes, C. Hermans, K. Peerlinck, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Postural control during a transition task in haemophilic children, adolescents and young adults with haemophilic ankle arthropathy

F. Staes, C. Hermans, K. Peerlinck, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study

C. Hermans, H. Chambost, J. Mahlangu, 2013 .

Assessment of passive musculoarticular ankle stiffness in children, adolescents and young adults with haemophilic ankle arthropathy

C. Detrembleur, C. Hermans, K. Peerlinck, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Deficits of ankle muscle strength not found in children, adolescents and young adults with haemophilic ankle arthropathy

C. Hermans, J. Croisier, K. Peerlinck, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Biomechanical markers and theoretical concepts related to haemophilic ankle and subtalar joint arthropathy: introducing the term ‘haemophilic tarsal pan‐arthropathy’

F. Staes, C. Hermans, K. Peerlinck, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement

K. Peerlinck, D. Van den Bossche, M. Jacquemin, 2018, International journal of laboratory hematology.

Falling and fall risk factors in adults with haemophilia: an exploratory study

K. Milisen, K. Peerlinck, E. Vlaeyen, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

M F Hoylaerts, J. Vermylen, L. Vander Elst, 1998, Blood.

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.

J. Arnout, H. Deckmyn, J. Vermylen, 1993, The Journal of clinical investigation.

The biomechanical behaviour of ankle and foot joints during walking with shoes in patients with haemophilia

F. Staes, C. Hermans, K. Peerlinck, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Medical co‐morbidities of patients with haemophilia: pain, obesity and hepatitis C

B. Luxon, M. Witkop, K. Peerlinck, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Dominant C2 Domain Epitope Specificity of Inhibitor Antibodies Elicited by a Heat Pasteurized Product, Factor VIII CPS-P, in Previously Treated Hemophilia A Patients without Inhibitors

M. van den Berg, K. Peerlinck, E. Mauser-Bunschoten, 1998, Thrombosis and Haemostasis.

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

J. Astermark, C. Hermans, Michael Wang, 2020 .

Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.

W. Ageno, M. Prins, P. Verhamme, 2013, Thrombosis and haemostasis.

Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.

P. Verhamme, K. Peerlinck, J. Saint-Remy, 2010, Clinical therapeutics.

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.

William J. Astle, Suthesh Sivapalaratnam, Kathleen Stirrups, 2017, Blood.

Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A

J. Astermark, J. Oldenburg, C. Hermans, 2013 .

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series

A. Iorio, T. Lambert, M. Makris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

UK Haemophilia Centre Doctors’ Organisation guidance on the use of extended‐half‐life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters

C. Hermans, G. Dolan, K. Peerlinck, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Review of the Hepatitis A Epidemics in Hemophiliacs in Europe

J. Vermylen, J. Vermylen, K. Peerlinck, 1994, Vox sanguinis.

In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization.

J. Arnout, J. Vermylen, K. Peerlinck, 1991, Acta clinica Belgica.

Practical and cost‐effective measurement of B‐domain deleted and full‐length recombinant FVIII in the routine haemostasis laboratory

K. Peerlinck, M. Jacquemin, J. Toelen, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Measurement of B‐domain‐deleted ReFacto AF activity with a product‐specific standard is affected by choice of reagent and patient‐specific factors

K. Peerlinck, M. Jacquemin, A. Vodolazkaia, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool.

A. Luttun, K. Peerlinck, J. Saint-Remy, 2010, Blood.

Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study

K. Peerlinck, C. Van Geet, K. Freson, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII solutions in pre-filled syringes

J. Vermylen, J. Arnout, K. Peerlinck, 1992, The Lancet.

Mutations in the fibrinogen aalpha gene account for the majority of cases of congenital afibrinogenemia.

S. Antonarakis, C. Rossier, M. Morris, 2000, Blood.

Inhibitor development in mild and moderate hemophilia A seems to be associated with an increased mortality risk

J. Astermark, P. Kamphuisen, J. Bom, 2011 .

The concentration of GPIbα magnetic particles is a critical parameter occasionally responsible for poor reproducibility of the VWF:GPIbR chemiluminescent immunoassay

K. Peerlinck, M. Jacquemin, I. Vanlinthout, 2019, International journal of laboratory hematology.

Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII

K. Peerlinck, M. Jacquemin, E. Sokal, 2014, Journal of thrombosis and haemostasis : JTH.

Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors.

J. Arnout, J. Vermylen, K. Peerlinck, 1997, Thrombosis and haemostasis.

Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha‐2b interferon is not a predictor for sustained response to treatment

F. Nevens, J. Vermylen, K. Peerlinck, 1994, British journal of haematology.

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Sri V. V. Deevi, W. Ouwehand, A. Attwood, 2016, Blood.

De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures

Henning Gall, Fengyuan Hu, Kevin Rue-Albrecht, 2018, American journal of human genetics.

Whole-genome sequencing of patients with rare diseases in a national health system

Keith W. Muir, William J. Astle, Mark I. McCarthy, 2020, Nature.

Confirmatory strategy of hepatitis C serology based on two screening assays in a diagnostic setting.

F. Nevens, K. Peerlinck, J. Desmyter, 1997, Acta clinica Belgica.

Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.

M. Hoylaerts, H. Deckmyn, J. Vermylen, 1995, The Biochemical journal.

Whole-genome sequencing of a sporadic primary immunodeficiency cohort

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2020, Nature.

A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature

K. Peerlinck, M. Jacquemin, K. Van Calsteren, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

The Molecular Basis of Antithrombin Deficiency in Belgian and Dutch Families

S. Seneca, W. Lissens, I. Liebaers, 1998, Thrombosis and Haemostasis.

Failure to Detect Hepatitis A Virus RNA in Factor VIII Concentrates Using the Polymerase Chain Reaction: Results of a Preliminary Study

P. Simmonds, F. Mcomish, P. Yap, 1994, Vox sanguinis.

TTV infection and its relation to serum transaminases in apparently healthy blood donors and in patients with clotting disorders who have been investigated previously for hepatitis C virus and GBV‐C/HGV infection in Belgium

C. Verslype, J. Vermylen, K. Peerlinck, 2002, Journal of medical virology.

Anti-hepatitis G E2 Antibody Detection and Its Relation to Serum HGV-RNA in Patients with Clotting Disorders: High Prevalence of HGV Infection and Spontaneous Remission

C. Verslype, S. Yap, J. Vermylen, 1998, Thrombosis and Haemostasis.

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

R. Dolmetsch, J. Astermark, C. Hermans, 2023, The New England journal of medicine.

Whole-genome sequencing of patients with rare diseases in a national health system

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2020, Nature.

Is the Apparent Outbreak of Hepatitis A in Belgian Hemophiliacs due to a Loss of Previous Passive Immunity?

J. Vermylen, K. Peerlinck, J. Desmyter, 1994, Vox Sanguinis.

A comprehensive high-throughput sequencing test for the diagnosis of inherited bleeding , thrombotic and platelet disorders

Sri V. V. Deevi, W. Ouwehand, J. Jolley, 2015 .

Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men

Gail Murphy, J. Vermylen, J. Barrett, 1994, Clinical pharmacology and therapeutics.

Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial.

P. Moons, S. Fieuws, W. Peetermans, 2013 .

Inhibitory and activating human antiplatelet antibodies.

H. Deckmyn, K. Peerlinck, K. Vanhoorelbeke, 1998, Bailliere's clinical haematology.

Acquired haemophilia A in a patient with systemic sclerosis treated with autologous haematopoietic stem cell transplantation.

G. Verleden, W. Wuyts, R. Westhovens, 2015, Rheumatology.

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

E. Lerut, M. Delforge, K. Peerlinck, 2016, Case reports in hematology.

Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension

Fengyuan Hu, Kevin Rue-Albrecht, Patrick Deegan, 2017, Circulation.

Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype

J. Oldenburg, T. Lambert, B. Guillet, 2003 .

An integrated proteomics and genomics analysis to unravel a heterogeneous platelet secretion defect.

Etienne Waelkens, Chantal Thys, Kathleen Freson, 2011, Journal of proteomics.

The TUBB 1 Q 43 P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure

J. Vermylen, L. Vanhees, K. Peerlinck, 2005 .

development destroys a major FVIII antigenic determinant involved in inhibitor hemophilia A by impairing FVIII binding to VWF and phospholipids and Deletion of alanine 2201 in the FVIII C2 domain results in mild

J. Vermylen, C. Négrier, K. Peerlinck, 2013 .

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

J. Vermylen, C. Négrier, K. Peerlinck, 2004, Blood.

Deletion of residue Ala2201 in the Factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by Factor VIII inhibitor antibodies

B. Stoddard, J. Vermylen, K. Peerlinck, 2001 .

Hepatitis G Viral RNA in Serum and in Peripheral Blood Mononuclear Cells and Its Relation to HCV-RNA in Patients with Clotting Disorders

C. Verslype, J. Pelt, S. Yap, 1997, Thrombosis and Haemostasis.

Parvovirus B19 Antibodies in Patients with Haemophilia A

J. Vermylen, K. Peerlinck, J. Desmyter, 1995, Thrombosis and Haemostasis.

Abstract

J. Oldenburg, B. Guillet, A. Rafowicz, 2003 .

structure cardiovascular disease in men by modulating platelet function and The TUBB1 Q43P functional polymorphism reduces the risk of

J. Vermylen, L. Vanhees, K. Peerlinck, 2013 .

Coagulation Factors Accumulate During Normothermic Liver Machine Perfusion Regardless of Donor Type and Severity of Ischemic Injury

P. Friend, R. Ploeg, L. Libbrecht, 2021, Transplantation.

structure cardiovascular disease in men by modulating platelet function and Q43P functional polymorphism reduces the risk of TUBB1 The

J. Vermylen, L. Vanhees, K. Peerlinck, 2009 .

Acquired von Willebrand Syndrome in left Impella supported cardiogenic shock patients

P. Verhamme, T. Adriaenssens, K. Peerlinck, 2020 .

Quantifying clinical misinterpretations associated to one-segment kinetic foot modelling in both a healthy and patient population.

F. Staes, K. Peerlinck, K. Deschamps, 2019, Clinical biomechanics.

A VITAMIN K ANTAGONIST RAPIDLY REVERSES A BLUE TOE SYNDROME IN A PATIENT WITH LUPUS ANTICOAGULANT AND ANTIPROTHROMBIN ANTIBODIES

J. Arnout, J. Vermylen, R. Verhaeghe, 2002, Acta clinica Belgica.

Arterial occlusion and thrombus aspiration after total knee arthroplasty.

J. Bellemans, J. Vermylen, K. Peerlinck, 1999, Clinical orthopaedics and related research.

PBI55 Patient Preferences for GENE Therapy in Hemophilia: Results from the Paving Threshold Technique Survey

S. Simoens, I. Huys, C. Hermans, 2020 .

cofactor activity and binding to von Willebrand factor A human antibody directed to the factor VIII C1 domain inhibits factor VIII

J. Vermylen, K. Thielemans, R. Schwaab, 2013 .

A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor

J. Vermylen, K. Peerlinck, J. Saint-Remy, 1997 .

Factor VIII inhibitor: affinity is the clue.

K. Peerlinck, M. Jacquemin, 2015, Blood.

THROMBOSIS AND HEMOSTASIS A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders